, a leading global ingredient solutions provider to the food and beverage industry, for the exclusive licensing of Amyris’s zero-calorie, nature-based, fermented Reb M sweetener.
– The combination of Amyris’s leading synthetic biology technology platform to develop, scale and produce fermentation-based products with Ingredion’s global market and customer reach, formulation capabilities and commercial teams will accelerate the availability and adoption of zero-calorie, nature-based sweeteners and other clean labeled fermentation-based food ingredients to the world’s leading food and beverage companies.
This includes $75 million for the exclusive license to sell and market Reb M from fermentation plus a contribution for a participation in the Brazil manufacturing joint venture.
“We are very much looking forward to this new partnership.
With Ingredion Idea Labs® innovation centers located around the world and approximately 12,000 employees, the Company co-creates with customers and fulfills its purpose of bringing the potential of people, nature and technology together to make life better.
Amyris is proud to own three consumer brands – all built around its No Compromise® promise of clean ingredients: Biossance® clean beauty skincare, Pipette® clean baby skincare and Purecane™, a zero-calorie sweetener naturally derived from sugarcane.
For Ingredion:This news release contains or may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are based on current circumstances or expectations, but are subject to certain inherent risks and uncertainties, many of which are difficult to predict and beyond our control.
Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement as a result of new information or future events or developments.
These statements are based on Amyris management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to realizing the expected benefits of strategic partnerships and collaborations; potential delays or failures in successfully closing the transaction with Ingredion; potential delays or failures in development, production, regulatory approval and commercialization of products; Amyris’s reliance on third parties ; Amyris’s liquidity and ability to fund operating and capital expenses; and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.